Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction

Vaccine

Volumn 35, Issue 52, 2017, Pages 7217-7221

  Ding, Lili ^a,b   Widdice, Lea E ^a,b   Kahn, Jessica A ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Human papillomavirus; Vaccine; Women

Indexed keywords

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGE; ARTICLE; CONDOM USE; FEMALE; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; MEDICAID; PRIORITY JOURNAL; SEXUAL BEHAVIOR; VACCINATION; WART VIRUS; WOMEN'S HEALTH; CROSS-SECTIONAL STUDY; EPIDEMIOLOGICAL MONITORING; GENETICS; HERD IMMUNITY; IMMUNOLOGY; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PREVALENCE; STATISTICS AND NUMERICAL DATA; UNITED STATES; VAGINA; VIROLOGY; YOUNG ADULT;

WART VIRUS VACCINE;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMANS; IMMUNITY, HERD; MEDICAID; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; SEXUAL BEHAVIOR; UNITED STATES; VACCINATION; VAGINA; YOUNG ADULT;

EID: 85034599669     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.11.005     Document Type: Article

References (22)

1. Kahn, J.A., Widdice, L.E., Ding, L., Huang, B., Brown, D.R., Franco, E.L., et al. Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community. Clin Infect Dis 63 (2016), 1281–1287.
2. Garland, S.M., Kjaer, S.K., Munoz, N., Block, S.L., Brown, D.R., DiNubile, M.J., et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis 63 (2016), 519–527.
3. Cameron, R.L., Kavanagh, K., Pan, J., Love, J., Cuschieri, K., Robertson, C., et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009–2013. Emerg Infect Dis 22 (2016), 56–64.
4. Kavanagh, K., Pollock, K.G., Potts, A., Love, J., Cuschieri, K., Cubie, H., et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. British J Cancer 110 (2014), 2804–2811.
5. Mesher, D., Soldan, K., Lehtinen, M., Beddows, S., Brisson, M., Brotherton, J.M., et al. Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes. Emerg Infect Dis 22 (2016), 1732–1740.
6. Wheeler, C.M., Castellsague, X., Garland, S.M., Szarewski, A., Paavonen, J., Naud, P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13 (2012), 100–110.
7. Chen, Z., DeSalle, R., Schiffman, M., Herrero, R., Burk, R.D., Evolutionary dynamics of variant genomes of human papillomavirus types 18, 45, and 97. J Virol 83 (2009), 1443–1455.
8. Tota, J.E., Jiang, M., Ramanakumar, A.V., Walter, S.D., Kaufman, J.S., Coutlee, F., et al. Epidemiologic evaluation of human papillomavirus type competition and the potential for type replacement post-vaccination. PLoS One, 11, 2016, e0166329.
9. Tota, J.E., Struyf, F., Merikukka, M., Gonzalez, P., Kreimer, A.R., Bi, D., et al. Evaluation of type replacement following HPV16/18 vaccination: pooled analysis of two randomized trials. J Natl Cancer Inst, 109, 2017.
10. Soderlund-Strand, A., Uhnoo, I., Dillner, J., Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study. Cancer Epidemiol Biomarkers Prevent: Publ Am Assoc Cancer Res Cospons Am Soc Prev Oncol 23 (2014), 2757–2764.
11. Saccucci, M., Franco, E.L., Ding, L., Bernstein, D.I., Brown, D.R., Kahn, J.A., Non-vaccine-type HPV prevalence after vaccine introduction: no evidence for type replacement but evidence for cross-protection. Sex Transm Dis, 2017 (in press).
12. Dunne, E.F., Unger, E.R., Sternberg, M., McQuillan, G., Swan, D.C., Patel, S.S., et al. Prevalence of HPV infection among females in the United States. J Am Med Assoc 297 (2007), 813–819.
13. Fisher, H., Trotter, C.L., Audrey, S., MacDonald-Wallis, K., Hickman, M., Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis. Int J Epidemiol 42 (2013), 896–908.
14. Herrero, R., Castle, P.E., Schiffman, M., Bratti, M.C., Hildesheim, A., Morales, J., et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Inf Dis 191 (2005), 1796–1807.
15. Kahn, J.A., Lan, D., Kahn, R.S., Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol 110 (2007), 87–95.
16. Markowitz, L.E., Hariri, S., Lin, C., Dunne, E.F., Steinau, M., McQuillan, G., et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Inf Dis 208 (2013), 385–393.
17. Miller, S., Wherry, L.R., Health and access to care during the first 2 years of the ACA Medicaid expansions. N Engl J Med 376 (2017), 947–956.
18. Shi, R., Devarakonda, S., Liu, L., Taylor, H., Mills, G., Factors associated with genital human papillomavirus infection among adult females in the United States, NHANES 2007–2010. BMC Res Notes, 7, 2014, 544.
19. Shikary, T., Bernstein, D.I., Jin, Y., Zimet, G.D., Rosenthal, S.L., Kahn, J.A., Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women. J Clin Virol 46 (2009), 107–111.
20. Kahn, J.A., Rosenthal, S.L., Jin, Y., Huang, B., Namakydoust, A., Zimet, G.D., Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol 111 (2008), 1103–1110.
21. Gravitt, P.E., Peyton, C.L., Alessi, T.Q., Wheeler, C.M., Coutlee, F., Hildesheim, A., et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 38 (2000), 357–361.
22. Hariri, S., Unger, E.R., Sternberg, M., Dunne, E.F., Swan, D., Patel, S., et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003–2006. J Infectious Dis 204 (2011), 566–573.